Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Chief Accounting Officer | November 02, 2021 | November 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date November 02, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 29,673 |
Reported balance
After 2021-11-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-02 · Grant · Acquired 29,673 · Balance 29,673 F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on November 2, 2021, with 7,418 vesting on each of November 2, 2022, March 5, 2023 and March 5, 2024 and 7,419 vesting on March 5, 2025. F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2: Restricted share units were granted on November 2, 2021, with 7,418 vesting on each of November 2, 2022, March 5, 2023 and March 5, 2024 and 7,419 vesting on March 5, 2025.
F3: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2021 Filed Nov 4, 2021 11:27 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 29,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-062869 · doc4.xml · derivative · entry 1 Weil Andrew · CIK 0001845020 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,673 Underlying: Ordinary Shares · 29,673 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on November 2, 2021, with 7,418 vesting on each of November 2, 2022, March 5, 2023 and March 5, 2024 and 7,419 vesting on March 5, 2025. F2 · derivative.expiration_date: Restricted share units were granted on November 2, 2021, with 7,418 vesting on each of November 2, 2022, March 5, 2023 and March 5, 2024 and 7,419 vesting on March 5, 2025. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.